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August 2009 and February 2011. Basic demographic vari-
ables, present use of OAC, severity of stroke, cardiovascular 
risk factors, INR values and the symptom onset to presenta-
tion time were recorded. In IS patients on OAC presenting 
within 4.5 h after symptom onset, management was ana-
lyzed. In thrombolysed IS patients, bleeding events were 
documented. Outcome was assessed after 3 months.  Re-
sults: During the study period, 12,237 patients were admit-
ted to our neurological ER. IS or TIA were diagnosed in 2,074 
(16.9%). Complete data were available for 1,914 of these sub-
jects (92.3%); 53.8% were male (median age: 72 years). 69.7% 
suffered IS, 30.3% TIA. OAC were being used by 8.7% of all 
patients. OAC patients were older than non-OAC patients (78 
vs. 72 years, p  ! 0.001). Subtherapeutic INR values ( ! 2.0) 
were found in 67.3% of OAC patients with IS. 54.8% of all OAC 
IS patients presented at the ER within  ^  4.5 h after the event 
(57/104). An INR  ^  1.7 – compatible with systemic thrombol-
ysis – was present in 33/57 patients (57.9%). Recanalization 
therapy was performed in 21/57 patients (36.8%). No differ-
ence in symptomatic or fatal intracerebral bleedings be-
tween thrombolysed patients with and without prior OAC 
use was observed (p = 0.720 and 0.135, respectively). Multi-
variable analysis of predictors of the 3-month outcome in IS 
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 Abstract
 Background: The emergency management of patients with 
acute ischemic stroke (IS) using oral anticoagulants (OAC) 
represents a great challenge. Effective anticoagulation pre-
disposes to bleeding and represents a contraindication for 
systemic thrombolysis. However, patients on OAC can re-
ceive intravenous thrombolysis with recombinant tissue-
type plasminogen activator if the international normalized 
ratio (INR) does not exceed 1.7, but data regarding the risk of 
hemorrhagic complications are highly controversial. Neuro-
interventional recanalization of intracranial artery occlusion 
represents an alternative option in OAC patients with acute 
IS. The proportion of OAC users among consecutive patients 
who suffer from acute IS or transient ichemic attacks (TIA) is 
unknown.  Methods: A prospective observational study, con-
secutively enrolling all patients with IS or TIA admitted to our 
neurological emergency room (ER), was performed between 
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patients revealed that prior medication with OAC was nei-
ther associated with an unfavorable clinical outcome after 3 
months in the whole population of stroke patients (p = 0.235) 
nor in patients in whom recanalization approaches were 
used (n = 306; p = 0.271).  Conclusions: Oral anticoagulation 
represents a frequent challenge for the emergency manange-
ment of IS. A considerable proportion of anticoagulated IS 
patients appears to be eligible for thrombolysis. Establishing 
standardized treatment procedures in these patients is war-
ranted.  Copyright © 2012 S. Karger AG, Basel
 Introduction
 Long-term oral anticoagulation (OAC) with vitamin 
K antagonists and a target international normalized ratio 
(INR) of 2–3 constitutes a very effective strategy for pre-
venting stroke in patients suffering from atrial fibrilla-
tion (AF)  [1–3] . Moreover, OACs are used to prevent 
thromboembolic events in patients with artificial heart 
valves  [4] and for preventing recurrent deep vein throm-
bosis and pulmonary embolism  [5, 6] . However, subther-
apeutic INR levels in OAC patients are reported to be 
present in 24–45% in population-based studies  [7–9] and 
at the time of stroke subtherapeutic INR values are pres-
ent in 62–68% of AF patients  [10, 11] .
 Thrombolysis with recombinant tissue-type plasmin-
ogen activator (rtPA) within a 4.5-hour time window after 
symptom onset is the only approved medical therapy in 
acute ischemic stroke (IS), although it increases the risk of 
brain hemorrhage  [12] . The emergency management of 
patients with acute IS during oral anticoagulation with 
OAC is particularly challenging because effective antico-
agulation predisposes to bleeding and represents there-
fore a contraindication for systemic thrombolysis.
 According to current guidelines, patients on OAC can 
receive intravenous thrombolysis with rtPA if the INR 
does not exceed 1.7  [13] , although data regarding the risk 
of hemorrhagic complications are controversial  [14–19] . 
Neurointerventional recanalization of proximal intra-
cranial artery occlusion represents an alternative option 
in OAC patients, but the available evidence regarding ef-
ficacy and safety of such procedures in general and in this 
particular setting is limited  [20, 21] .
 Available studies on the prevalence of OAC at the time 
of an acute cerebrovascular event are based on noncon-
secutive cohorts  [7, 10, 19, 22] , did not include transient 
ischemic attack (TIA) patients  [7, 9–11, 17, 19, 22] or fo-
cussed exclusively on patients who underwent thrombol-
ysis  [7, 10, 11, 17, 19, 22] . A European multicenter study 
revealed OAC rates of about 4% in first ever stroke pa-
tients  [23] . Examining changes in stroke incidence and 
risk factors, Rothwell et al.  [24] reported a rising number 
of patients receiving OAC at the time of stroke between 
1981 (1.1%) and 2004 (3.8%). Importantly – due to demo-
graphic changes – it is expected that the number of 
 patients using OAC will further rise steeply. However, 
 despite its practical importance, emergency room (ER)-
based studies on the prevalence of OAC in consecutive 
patients with acute cerebrovascular events have not been 
performed to our knowledge.
 The purpose of the present study was to determine the 
proportion of patients using OAC in a consecutive acute 
IS and TIA cohort in a neurological ER. We evaluated the 
intensity of anticoagulation at the time of the event and 
documented the subsequent clinical management and 
outcome in OAC IS patients presenting within 4.5 h after 
symptom onset. Furthermore, we documented bleeding 
events in patients treated with rtPA.
 Methods
 This prospective observational study was performed in the 
neurological ER of the University Hospital Heidelberg. Between 
August 2009 and February 2011, consecutive patients who pre-
sented with acute ischemic stroke or TIA were enrolled. The 
catchment area of our tertiary stroke center encompasses approx-
imately 850,000 inhabitants. Our hospital is the only provider of 
24-hour/7-day acute care for stroke patients in the region. Conse-
quently, the vast majority of patients suspected of suffering acute 
cerebrovascular events are primarily referred to our institution.
 In the ER, a neurological examination, laboratory work and 
brain imaging (CT or MRI) were performed in all patients. IS and 
TIA were diagnosed according to current guidelines  [13, 25] by 
neurologists experienced in stroke medicine. In ICH patients in 
whom evidence of secondary hemorrhages was present (i.e. hem-
orrhagic transformation of an infarct), a follow-up MRI in the 
acute phase and after 3 months was performed to differentiate 
between primary intracerebral hemorrhage and secondary hem-
orrhagic transformation.
 Using a standardized questionnaire, the present use of oral 
anticoagulants, the medical indication for OAC therapy, basic 
risk factors and INR values were documented. If patients were 
unable to answer questions regarding the medical history or 
medication (e.g. aphasic patients or patients with dementia), rel-
atives and the primary care physician were contacted. The Na-
tional Institutes of Health Stroke Scale  [26] was applied to mea-
sure the severity of stroke symptoms. Time from symptom onset 
to admission was recorded. All patients treated with rtPA re-
ceived CT or MRI within 24–36 h after thrombolysis or imme-
diately in case of clinical deterioration. Imaging was evaluated 
applying the SITS definitions  [27] by experienced stroke neu-
rologists and a neuroradiologist blinded to all clinical data. Neu-
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rological deterioration as indicated by a score on the National 
Institutes of Health Stroke Scale that was higher by  6 4 points 
than the baseline value was defined as symptomatic bleeding. 
Fatal bleeding was defined as in-hospital death due to intracra-
nial bleeding after treatment with rtPA.
 After 3 months, all patients or their relatives were interviewed 
by telephone for follow-up to assess the functional outcome using 
the modified Rankin scale (mRS) and standardized questions 
 [28] . The therapeutic INR range was defined as an INR of 2–3.
 The independent ethics committee of the medical faculty of 
the University of Heidelberg approved this study. Patients or their 
legal representatives gave informed consent.
 Statistical Analysis
 Most descriptive data are presented in relative frequencies, or-
dinal and continuous data as medians and interquartile ranges. 
Univariate nonparametric tests were applied to test all differences 
between stroke and TIA and between OAC users and non-OAC 
users. Additionally, binary logistic regression models were used 
to evaluate factors independently associated with clinical out-
come after 3 months. For this purpose, the mRS was dichoto-
mized (0–2 and 3–6). The logistic regressions were adjusted in a 
model for factors associated with stroke outcome (age, gender, 
CHADS 2  risk factors, medication with OAC, known AF and di-
chotomized initial National Institutes of Health Stroke Scale val-
ues  ! 10 and  1 10, respectiveley). A two-sided p value of  ! 0.05 was 
considered significant. Data analysis was performed using the 
Statistical Package for the Social Sciences (SPSS 19.0).
 Results
 Population Characteristics
 Figure 1 illustrates the composition of our population. 
During the study period (19 months) a total of 12,237 pa-
tients were admitted to our neurological ER. Intracere-
bral hemorraghes were present in 207 patients (1.7%). IS 
or TIA were diagnosed in 2,074 of the 12,237 patients 
(16.9%); 3-month follow-up data were available for 92.3% 
(5.9% lost to follow-up; 1.8% refusal to consent). Thus, the 
population entered into the analysis encompassed 1,914 
patients.
 The majority of patients suffered an IS (69.7%, n = 
1.335); TIAs were diagnosed in 30.3% (n = 579). TIA pa-
tients were significantly younger than patients with IS 
(p  ! 0.001;  table 1 ).
 Differences between Anticoagulated and 
Nonanticoagulated Patients
 In total, 167 of our stroke/TIA population (8.7%) were 
using OAC at the time of admission. The predominant 
reason for OAC use at the time of the event was AF (n = 
139). Other indications included mechanical heart valves 
Total admissions to the neurological ER (n = 12,237)
IS/TA (n = 2,074) Intracerebral hemorrhage (n = 207)
Lost to follow-up (n = 112)
Withdrew consent (n = 38)
Complete data set (n = 1,914)
OAC use (n = 104)
INR ≤1.7: 33 INR >1.7: 24
Thrombolysis: 15 (i.v.: 12; i.a.: 3) Mechanical recanalization + i.a.: 6
Non-OAC users (n = 1,231)
Presentation ≤4.5 h after onset 
 (n = 57)
OAC use (n = 63)
IS
69.7% (n = 1,335)
TIA 
30.3% (n = 579)Total OAC use
8.7% (n = 167)
Non-OAC users (n = 516)
 Fig. 1. Synopsis of the composition of our population including use of OAC and proportion of IS patients admit-
ted within 4.5 h after onset of symptoms. n = Number of patients; i.v. = intravenous; i.a. = intra-arterial. 
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(15), deep vein thrombosis or recent pulmonary embo-
lisms (7), persistent foramen ovale, hypertrophic cardio-
myopathy, thrombogenic aortic arch, antiphospholipid 
antibody syndrome, or unidentifiable reasons (n = 6). Pa-
tients using OAC were significantly older (median age 78 
vs. 72 years for non-OAC patients, p  ! 0.001) and they had 
more cardiovascular risk factors ( table 1 ). Moreover, OAC 
users more frequently had a history of previous stroke or 
TIA than non-OAC users (p  ! 0.001;  table 1 ).
 Quality of INR Control at the Time of the Event
 The median INR value in patients using OAC at the 
time of admission was 1.8 (1.4–2.4). The majority of 
stroke/TIA patients taking OAC (60.5%) had an INR  ! 2 
at presentation; 30.5% had INR values between 2.0 and 
3.0, and 9% had INR values  1 3.0 ( table 2 ). Subtherapeutic 
INR values ( ! 2.0) were found in 67.3% of anticoagulated 
patients with IS and were more often observed in stroke 
than in TIA patients (p = 0.045;  table 2 ). A previous cere-
brovascular event did not predict whether INR values 
were within the therapeutic range (p = 0.897).
 Acute IS in OAC Patients
 OAC were used by 7.8% of all IS patients at the time of 
the event (104/1,335). The median time between symp-
tom onset and presentation at the ER for the 104 OAC 
patients with IS was 3.6 h (1.6–19.8). Of these 104 patients, 
57 (54.8%) presented within the time window for system-
ic thrombolysis (i.e.  ^  4.5 h after the event;  fig. 1 ). The 
median INR in OAC patients presenting within the 4.5-
hour time window was 1.5 (1.2–2.2). An INR  ^  1.7 – com-
patible with systemic thrombolysis – was present in 33/57 
patients (57.9%). Consequently, 33/104 OAC patients with 
IS fulfilled time and coagulation criteria for systemic 
thrombolysis (31.7%). Systemic thrombolysis was per-
formed in 12 of these 33 patients; 3/33 patients underwent 
a combined intravenous/intra-arterial procedure ( fig. 1 ). 
Reasons not to intervene with systemic administration of 
rtPA in patients with an INR  ^  1.7 encompassed age  1 80 
years and associated severe premorbid disability (6), mi-
nor or shrinking neurological deficits (6), absent mis-
match on MRI images (2), recent surgical interventions 
(2), seizures at symptom onset (1), neoplasias (1) or a com-
bination of these.
 Moreover, another 6 OAC stroke patients presenting 
within 4.5 h after symptom onset but with an INR  1 1.7 
on admission were treated using mechanical neuroradio-
logical recanalization approaches in combination with 
rtPA ( fig. 1 ).
 Intracerebral Bleeding following Thrombolytic 
Therapy
 In total 320/1,335 IS patients (24.0%) were treated with 
rtPA; either intravenously (79.1%), intra-arterially (5.3%), 
by a combined intravenous/intra-arterial approach 
(14.4%) or by continuous intravenous rtPA infusion for 
24 h (0.9%).
 Of the 320 IS patients receiving thrombolysis, a CT 
was performed in 260 as initial brain imaging. In 22/320, 
an MRI was done and in 38/320 both CT and MRI were 
performed initially. Follow-up imaging in these 320 pa-
tients was done with CT in 257, with MRI in 25 and with 
both CT and MRI in 35. All OAC patients that were 
thrombolysed (n = 21) had CT as initial brain imaging. 
Follow-up imaging in the OAC patients receiving throm-
bolysis was done by CT in 18, by MRI in 1 and by CT and 
MRI in 2 patients.






 Age, years   
 Median  72  78  <0.001 
 IQR  61–80  71–84 
 Male sex, %  53.7  54.5 0.843 
 Stroke, %  70.5  62.3 0.028 
 TIA, %  29.5  37.7 0.028 
 Congestive heart failure, % 9.2  24.0  <0.001 
 Arterial hypertension, %  76.8  83.2 0.058 
 Diabetes, %  24.0  30.5 0.063 
 Previous stroke/TIA, %  23.0  36.5  <0.001 
 I QR = Interquartile range. 
 Table 2. D istribution of INR values in OAC users of the entire 
population and risk of suffering stroke and TIA, respectively, in 
OAC patients in comparison with non-OAC users
 Total OAC
 (n = 167) 
 Stroke
 (n = 104) 
 TIA
 (n = 63) 
 p 
 INR <2.0  101 (60.5)  70 (67.3)  31 (49.2)  0.045 
 INR ≥2.0 to ≤3.0 51 (30.5)  27 (26)  24 (38.1)  0.621 
 INR >3.0 15 (9) 7 (6.7) 8 (12.7)  0.226 
 F igures in parentheses are percentages.  
 Oral Anticoagulants in the Neurological 
Emergency Room 
Cerebrovasc Dis 2012;34:411–418 415
 Overall, any intracerebral hemorrhage according to 
SITS criteria (i.e. including hemorraghic transformation) 
after administration of rtPA occurred in  18/320 patients 
(5.6%; 16 in patients without and 2 in patients with prior 
OAC use; p = 0.33). Fatal intracerebral bleeding after 
thrombolysis ocurred in 10/320 patients (3.1%; without 
prior OAC medication: 8/290 (2.8%); with prior OAC 
medication: 2/21 (9.5%); p = 0.135).
 Outcome Results
 Good outcome (mRS 0–2) was less common (p = 0.001) 
in patients with OAC (37/104; 35.6%) than in other IS pa-
tients (649/1,231; 52.7%). Multivariable analysis of predic-
tors of the 3-month outcome in IS patients are presented 
in  table 3 . Female sex (p  ! 0.001), higher age (p  ! 0.001), 
diabetes (p  ! 0.001), prior stroke events (p = 0.035) and 
higher initial NIHSS score (p  ! 0.001) predicted unfavor-
able outcome (mRS 3–6). In contrast, prior medication 
with OAC was neither associatd with an unfavorable clin-
ical outcome after 3 months in the whole population of 
stroke patients (p = 0.235) nor in patients in whom re-
canalization approaches were performed (n = 306; p = 
0.271).
 An exploratory post hoc analysis to evaluate an impact 
of OAC medication on the initial NIHSS in AF IS patients 
of our cohort revealed that the risk of suffering a severe 
stroke (defined as NIHSS  1 10) at presentation was higher 
in AF IS patients who were not on OAC (OR = 2.024, 95% 
CI = 1.178–3.477, p = 0.011). However, we did not find an 
association between INR values (INR  ! 2, 2–3 and  1 3) and 
initial NIHSS scores in OAC AF IS patients (p = 0.411).
 Moreover, we evaluated outcome at 3 months (mRS) 
in the IS AF patients who were anticoagulated versus 
those who were not anticoagulated: No association be-
tween clinical outcome and OAC status (anticoagulated 
vs. not anticoagulated) was present in the 258 IS AF pa-
tients (OR = 1.0; 95% CI = 0.576–1.737, p = 1.0). Moreover, 
no association between initial INR values and the 
3-month outcome was observed (p = 0.236;  table 4 ).
 Table 3. P redictors of 3-month outcome in IS patients (n = 1,335)
 mRS 0–2 (n = 686)  mRS 3–6 (n = 649) OR1  95% CI p value 
 Male sex  444 (64.7)  288 (44.4) 0.568  0.438–0.737  <0.001 
 Age >75 years  198 (28.9)  403 (62.1) 0.275  0.211–0.358  <0.001 
 Hypertension  515 (75.1)  536 (82.6) 0.789  0.571–1.091 0.151 
 Diabetes  149 (21.7)  199 (30.7) 0.581  0.433–0.780  <0.001 
 Prior stroke  150 (21.9)  172 (26.5) 0.724  0.536–0.978 0.035 
 Chronic heart failure 55 (8.0) 96 (14.8) 0.866  0.565–1.326 0.508 
 OAC medication 37 (5.4) 67 (1.5) 0.714  0.409–1.246 0.235 
 Initial NIHSS >10 42 (6.1)  273 (42.1)  11.962  8.200–17.451  <0.001 
 Known AF 84 (12.2)  174 (26.8) 0.940  0.627–1.410 0.766 
 mRS 0–2 (n = 121)  mRS 3–6 (n = 185) OR  95% CI p value 
 OAC in patients who underwent
 recanalization approaches (n = 306) 
 
 4 (3.3) 
 




 0.121–1.808 0.271 
 O utcome of IS was assessed using the mRS and was dichotomized as 0–2 and 3–6. Figures in parentheses are percentages.
 1 Model adjusted for sex, age, congestive heart failure, arterial hypertension, diabetes, prior stroke, known AF, National Institutes 
of Health Stroke Scale (NIHSS) scores >/<10. 
 Table 4. O utcome in anticoagulated and nonanticoagulated IS 
 patients with AF and INR values
 AF patients of the IS cohort (n = 258) 
 no OAC
 (n = 172) 
 O AC yes (n = 86) 
INR <2 INR 2–3 INR >3 total
 mRS 0–2 56 (32.6)  24 4  0  28 (32.6) 
 mRS 3–6  116 (67.4)  41  14  3  58 (67.4) 
 Initial NIHSS score 
 <10 87 (50.6)  44  11  3  58 (67.4) 
 >10 85 (49.4)  21 7  0  28 (32.6) 
 Fig ures in parentheses are percentages.
 NIHSS = National Institutes of Health Stroke Scale. 
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 Discussion
 Our study underlines that OAC poses an important 
challenge for the emergency management of stroke. The 
major findings of our study are: (1) a substantial propor-
tion of acute IS (7.8%) and TIA (10.9%) patients are anti-
coagulated at the time of the event; (2) the majority of 
OAC patients with cerebrovascular events have INR val-
ues below the therapeutic INR range of 2–3 established 
for most prophylactic indications; (3) about one third of 
the anticoagulated IS patients presenting inside the time 
window had low INR values compatible with intravenous 
thrombolysis; (4) overall, prior medication with OAC did 
not predict outcome at 3 months in IS patients, and (5) no 
difference in bleeding events between thrombolysed pa-
tients with and without prior OAC use was observed.
 Although it is well known that patients may suffer IS 
despite oral anticoagulation, prospective studies consec-
utively enrolling acute IS patients and evaluating the im-
pact of OAC use on stroke management in the neurolog-
ical ER are sparse. Paciaroni et al.  [9] reported that 4.2% 
of acute ischemic stroke patients used anticoagulants 
alone or in combination with antiplatelets at the time of 
hospital admission. Evaluating data from the Oxford 
Community Stroke Project and the Oxford Vascular 
Study between 1981 and 2004 revealed that the number 
of patients receiving OAC at the time of stroke is rising 
(from 1.1 to 3.8%)  [24] . In contrast, about 8% of patients 
with an ischemic cerebrovascular event were using OAC 
at symptom onset in our study. Thus, orally anticoagu-
lated IS patients represent a substantial proportion of the 
overall acute stroke population. Moreover, taking the 
aforementioned reports into account, our data may sug-
gest that the prevalence of stroke during OAC has in-
creased in the last decade.
 The present study took place before the introduction 
of the new OAC which are being used by a growing num-
ber of patients. The rate of IS did not or only slightly dif-
fer between patients receiving warfarin or any of the new 
OAC (rivaroxaban, apixaban, dabigatran) in large clinical 
trials for stroke prevention in AF  [29–31] . We assume that 
prevalence of IS patients using OAC in our study may give 
a good estimate of the number of IS patients under new 
OAC that can be expected during the course of the next 
few years. Prospective studies to evaluate optimal diag-
nostic and treatment procedures in this challenging sub-
group of stroke patients are therefore urgently required.
 Consistent with previous reports, the majority of OAC 
patients in our cohort (60.5%) were insufficiently antico-
agulated (INR  ! 2) at the time of the event: Hylek et al. 
 [10] studied the effect of the intensity of OAC on stroke 
severity and mortality in a nonconsecutive cohort of pa-
tients with AF: among 188 OAC patients, 62% had INR 
values  ! 2.0. O’Donnell et al.  [11] evaluated preadmission 
medication in consecutive AF patients and reported sub-
therapeutic INR values in 68% of IS patients on warfarin. 
Accordingly, the proportion of patients with an INR be-
low the target range is substantially higher in acute stroke 
patients than in patient cohorts presenting for various 
reasons in general ER (43%)  [8] .
 Our finding that the risk of suffering severe strokes 
(NIHSS  1 10 at presentation) is elevated in those AF IS 
patients that were not on OAC is in line with the general 
knowledge that OAC represent an effective prevention 
measure to suffer severe strokes. The most likely reason 
why we did not observe an association between severity 
of stroke and INR at admission and between initial INR 
values and disability measured by mRS after 3 months 
appears to be the fact that our study was not powered for 
this question. To evaluate severity or outcome in AF IS 
patients on oral anticoagulation with therapeutic INR 
values versus AF patients outside therapeutic INR values 
or without OAC, Hylek et al.  [10] included 13,559 AF pa-
tients into their study and O’Donnell et al. [11] studied a 
population of 948 AF IS patients. In contrast, the number 
of AF patients with IS in our population is only 258.
 Most stroke specialists consider patients with an INR 
 ^  1.7 to be eligible for systemic thrombolysis if therapy 
can be initiated within 4.5 h after symptom onset  [13] . 
Importantly, bedside point-of-care INR measurements 
can accelerate thrombolysis in acute IS patients on oral 
anticoagulants  [32] ; these measurements are particularly 
helpful when information regarding the OAC status (e.g. 
aphasic patients) is not available. In our consecutive co-
hort, 31.7% of anticoagulated IS patients presented with-
in 4.5 h and had INR values  ^  1.7. Importantly, recanali-
zation therapy was initiated in 36.8% of OAC IS patients 
presenting at the ER within 4.5 h after symptom onset.
 Data on the risk of hemorrhagic complications after 
thrombolysis in patients with prior use of anticoagulants 
and outcome findings in thrombolysed OAC IS patients 
are still limited and indeed highly controversial  [14–19] . 
Matute et al.  [16] reported that the use of intravenous 
thrombolysis appears to be safe in patients previously 
treated with OAC with INR levels  ! 2: 5.7% of 1,384 pa-
tients used OAC before intravenous rtPA treatment in 
this study; however, only data from thrombolysed pa-
tients were included into this multicenter study and no 
data on the overall use of OAC in stroke patients were 
presented. A recent observational study that used data 
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from the American Heart Association Get with the 
Guidelines Stroke Registry reports that 7.7% of acute IS 
patients treated with rtPA were receiving warfarin (n = 
1,802/23,437); the use of intravenous tPA among warfarin 
patients (INR  ^  1.7) was not associated with an increased 
risk to suffer sICH  [19] . On the other hand, a recent pro-
spective observational study suggests an increase in the 
risk for symptomatic intracranial and major systemic 
bleedings among patients that were thrombolysed and 
that received warfarin up to the day before stroke (n = 
15/548; 2.7%)  [18] . In our population, the proportion of 
thrombolysed stroke patients with prior OAC was 6.6% 
(21/320). Importantly, we did not observe differences in 
symptomatic or fatal intracerebral bleedings between 
thrombolysed patients with and without prior OAC use. 
In summary, these data indicate that a considerable pro-
portion of patients who suffer acute ischemic stroke dur-
ing OAC are eligible for emergency stroke treatments. 
The present study was not designed to particularly evalu-
ate the efficacy of therapeutic measures in OAC stroke 
patients. Nonetheless, OAC did not predict outcome in 
our population – neither in the entire cohort nor in pa-
tients that underwent recanalization approaches.
 Our study has limitations. Performance at a single ter-
tiary stroke center may have biased our results. However, 
our institution is the only primary care provider for acute 
stroke in the region, and consecutive patient enrollment 
should ensure a representative character of our data. 
Moreover, we did not use different definitions of symp-
tomatic hemorrhage after thrombolysis in our study, and 
the study was observational and treatment procedures 
were not prespecified limiting the assessment of effec-
tiveness and safety of recanalization therapy in OAC pa-
tients. Adequately powered prospective studies are need-
ed to resolve this issue.
 In conclusion, our findings emphasize that OAC at the 
onset of acute IS represents a frequent and highly relevant 
problem for the emergency management of IS. Diagnos-
tic and therapeutic measures should be established to 
meet this challenge. 
 References 
 1 Aguilar MI, Hart R: Oral anticoagulants ver-
sus antiplatelet therapy for preventing stroke 
in patients with nonvalvular atrial fibrilla-
tion and no history of stroke or transient 
ischemic attacks. Stroke 2008;  39:  1399–1400.
 2 Mi A, Hart R, La P: Oral anticoagulants ver-
sus antiplatelet therapy for preventing stroke 
in patients with non-valvular atrial fibrilla-
tion and no history of stroke or transient 
ischemic attacks (review). Cochrane Data-
base Syst Rev 2007;  3:CD001927.
 3 EAFT (European Atrial Fibrillation Trial) 
Study Group: Secondary prevention in non-
rheumatic atrial fibrillation after transient 
ischaemic attack or minor stroke. Lancet 
1993;  342:  1255–1262.
 4 Hirsh J, Guyatt G, Albers GW, Harrington R, 
Schünemann HJ, American College of Chest 
Physicians: Antithrombotic and thrombo-
lytic therapy: American College of Chest 
Physicians evidence-based clinical practice 
guidelines (8th edition). Chest 2008;  133: 
 110S–112S.
 5 Büller HR, Gallus AS, Pillion G, Prins MH, 
Raskob GE: Enoxaparin followed by once-
weekly idrabiotaparinux versus enoxaparin 
plus warfarin for patients with acute symp-
tomatic pulmonary embolism: a random-
ised, double-blind, double-dummy, non-in-
feriority trial. Lancet 2012;  379:  123–129.
 6 Kearon C, Gent M, Hirsh J, Weitz J, Kovacs 
M, Anderson D, Turpie AG, Green D, Gins-
berg JS, Wells P, MacKinnon B, Julian JA: A 
comparison of three months of anticoagula-
tion with extended anticoagulation for a first 
episode of idiopathic venous thromboembo-
lism. N Engl J Med 1999;  340:  901–907.
 7 Indredavik B, Rohweder G, Lydersen S: Fre-
quency and effect of optimal anticoagulation 
before onset of ischaemic stroke in patients 
with known atrial fibrillation. J Intern Med 
2005;  258:  133–144.
 8 Newman D, Zhitomirsky I: The prevalence 
of nontherapeutic and dangerous interna-
tional normalized ratios among patients 
receiving warfarin in the emergency de-
partment. Ann Emerg Med 2006;  48:  182–
182.
 9 Paciaroni M, Agnelli G, Caso V, Venti M, Al-
berti A, Milia P, Silvestrelli G, Biagini S: Pri-
or use of antithrombotic agents and neuro-
logical functional outcome at discharge in 
patients with ischemic stroke. J Thromb 
Haemost 2006;  4:  1957–1961.
 10 Hylek EM, Go AS, Chang Y, Jensvold NG, 
Henault LE, Selby JV, Singer DE: Effect of in-
tensity of oral anticoagulation on stroke se-
verity and mortality in atrial fibrillation. N 
Engl J Med 2003;  349:  1019–1026.
 11 O’Donnell M, Oczkowski W, Fang J, Kearon 
C, Silva J, Bradley C, Guyatt G, Gould L, 
Duva C, Kapral M, Silver F, Investigators of 
the Registry of the Canadian Stroke Net-
work: Preadmission antithrombotic treat-
ment and stroke severity in patients with 
atrial fibrillation and acute ischaemic stroke: 
an observational study. Lancet Neurol 2006; 
 5:  749–754.
 12 Lees K, Bluhmki E, Von Kummer R, Brott T, 
Toni D, Grotta J, Albers GW, Kaste M, Mar-
ler JR, Hamilton SA, Tilley BC, Davis SM, 
Donnan GA, Hacke W, Allen K, Mau J, Mei-
er D, del Zoppo G, De Silva DA, Butcher KS, 
Parsons MW, Barber PA, Levi C, Bladin C, 
Byrnes G: Time to treatment with intrave-
nous alteplase and outcome in stroke: an up-
dated pooled analysis of ECASS, ATLAN-
TIS, NINDS, and EPITHET trials. Lancet 
2010;  375:  1695–1703.
 13 Adams HP, del Zoppo G, Alberts MJ, Bhatt 
DL, Brass L, Furlan A, Grubb RL, Higashida 
RT, Jauch EC, Kidwell C, Lyden PD, Morgen-
stern LB, Qureshi AI, Rosenwasser RH, Scott 
PA, Wijdicks EFM: Guidelines for the early 
management of adults with ischemic stroke: 
a guideline from the American Heart Asso-
ciation/American Stroke Association Stroke 
Council, Clinical Cardiology Council, Car-
diovascular Radiology and Intervention 
Council, and the Atheros. Stroke 2007;  38: 
 1655–1711.
 14 Seet RCS, Zhang Y, Moore SA, Wijdicks EF, 
Rabinstein A: Subtherapeutic international 
normalized ratio in warfarin-treated pa-
tients increases the risk for symptomatic 
 intracerebral hemorrhage after intrave-
nous thrombolysis. Stroke 2011;  42:  2333–
2335.
 15 Kim YD, Lee JH, Jung YH, Choi HY, Nam 
CM, Yang JH, Cho HJ, Nam HS, Lee KY, Heo 
JH: Safety and outcome after thrombolytic 
treatment in ischemic stroke patients with 
high-risk cardioembolic sources and prior 
subtherapeutic warfarin use. J Neurol Sci 
2010;  298:  101–105.
 Rizos et al. Cerebrovasc Dis 2012;34:411–418418
 16 Matute M-C, Masjuan J, Egido J-A, Fuentes 
B, Simal P, Díaz-Otero F, Reig G, Diez-
Teedor E, Gil-Nunez A, Vivancos J, Lecinana 
MA: Safety and outcomes following throm-
bolytic treatment in stroke patients who had 
received prior treatment with anticoagu-
lants. Cerebrovasc Dis 2012;  33:  231–239.
 17 Meretoja A, Putaala J, Tatlisumak T, Atula S, 
Artto V, Curtze S, Häppölä O, Lindsberg PJ, 
Mustanoja S, Piironen K, Pitkäniemi J, Ran-
tanen K, Sairanen T, Salonen O, Silvennoi-
nen H, Soinne L, Strbian D, Tiainen M, Kaste 
M: Off-label thrombolysis is not associated 
with poor outcome in patients with stroke. 
Stroke 2010;  41:  1450–1458.
 18 Ruecker M, Matosevic B, Willeit P, Kirch-
mayr M, Zangerle A, Knoflach M, Willeit J, 
Kiechl S: Subtherapeutic warfarin therapy 
entails an increased bleeding risk after 
stroke thrombolysis. Neurology 2012;  79:  31–
38.
 19 Xiang Y, Liang L, Smith E, Schwamm L, 
Reeves MJ, Olson DM, Hernandez AF, Fon-
arow GC, Peterson ED: Risk of intracra -
 nial hemorrhage among patients with acute 
ischemic stroke receiving warfarin and 
treated with intravenous tissue plasmino -
 gen activator. JAMA 2012;  307:  2600–2608.
 20 Janjua N, Alkawi A, Georgiadis A, Suri MFK, 
Ibrahim MS, Kirmani JF, Qureshi AI: Feasi-
bility of IA thrombolysis for acute ischemic 
stroke among anticoagulated patients. Neu-
rocrit Care 2007;  7:  152–155.
 21 Linfante I, Reddy AS, Andreone V, Caplan 
LR, Selim M, Hirsch J: Intra-arterial throm-
bolysis in patients treated with warfarin. 
Cerebrovasc Dis 2005;  19:  133–135.
 22 Audebert HJ, Schenk B, Schenkel J, Heusch-
mann PU: Impact of prestroke oral antico-
agulation on severity and outcome of isch-
emic and hemorrhagic stroke in patients 
with atrial fibrillation. Cerebrovasc Dis 
2010;  29:  476–483.
 23 Di Carlo A, Lamassa M, Baldereschi M, Pra-
cucci G, Basile AM, Wolfe CDA, Giroud M, 
Rudd A, Ghetti A, Inzitari D, European 
BIOMED Study Care Group: Sex differences 
in the clinical presentation, resource use, 
and 3-month outcome of acute stroke in Eu-
rope. Stroke 2003;  34:  1114–1119.
 24 Rothwell PM, Coull AJ, Giles MF, Howard 
SC, Silver LE, Bull LM, Gutnikov SA, Ed-
wards P, Mant D, Sackley CM, Farmer A, 
Sandercock PAG, Dennis MS, Bamford JM, 
Anslow P, Oxford Vascular Study: Change in 
stroke incidence, mortality, case-fatality, se-
verity, and risk factors in Oxfordshire, UK, 
from 1981 to 2004 (Oxford Vascular Study). 
Lancet 2004;  363:  1925–1933.
 25 The European Stroke Organisation (ESO) 
Executive Committee and the ESO Writing 
Committee: Guidelines for management of 
ischaemic stroke and transient ischaemic at-
tack 2008. Cerebrovasc Dis 2008;  25:  457–507.
 26 Brott T, Adams HP, Olinger CP, Marler JR, 
Barsan WG, Biller J, Spilker J, Holleran R, 
Eberle R, Hertzberg V: Measurements of 
acute cerebral infarction: a clinical examina-
tion scale. Stroke 1989;  20:  864–870.
 27 Wahlgren N, Ahmed N, Davalos A, Ford GA, 
Grond M, Hacke W, Hennerici MG, Kaste M, 
Kuelkens S, Larrue V, Lees KR, Roine RO, 
Soinne L, Toni D, Vanhooren G, SITS-MOST 
investigators: Thrombolysis with alteplase 
for acute ischaemic stroke in the Safe Imple-
mentation of Thrombolysis in Stroke-Moni-
toring Study (SITS-MOST): an observation-
al study. Lancet 2007;  369:  275–282.
 28 Van Swieten JC, Koudstaal PJ, Visser MC, 
Schouten HJ, van Gijn J: Interobserver agree-
ment for the assessment of handicap in 
stroke patients. Stroke 1988;  19:  604–607.
 29 Patel MR, Mahaffey KW, Garg J, Pan G, 
Singer DE, Hacke W, Breithardt G, Halperin 
JL, Hankey GJ, Piccini JP, Becker RC, Nessel 
CC, Paolini JF, Berkowitz SD, Fox KAA, Cal-
iff RM, ROCKET AF steering committee for 
the ROCKET-AF investigators: Rivaroxaban 
versus warfarin in nonvalvular atrial fibril-
lation. N Engl J Med 2011;  365:  883–891.
 30 Granger CB, Alexander JH, McMurray JJ, 
Lopes RD, Hylek EM, Hanna M, Al-Khalidi 
HR, Ansell JA, Atar D, Avezum A, Bahit CM, 
Biaz R, Easton JD, Ezekowitz JA, Flaker G, 
Garcia D, Geraldes M, Gersh BJ, Golitsyn S, 
Goto S, Hermosillo AG, Hohnloser SH, 
Horowitz J, Mohan P, Jansky P, Lewis BS, Lo-
pez-Sendon JL, Pais P, Parkhomenko A, Ver-
heugt FWA, Zhu J, Wallentin L, ARISTOT-
LE committees and investigators: Apixaban 
versus warfarin in patients with atrial fibril-
lation. N Engl J Med 2011;  365:  981–992.
 31 Connolly SJ, Ezekowitz MD, Yusuf S, Eikel-
boom J, Oldgren J, Parekh A, Pogue J, Reilly 
PA, Themeles E, Varrone J, Wang S, Alings 
M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius 
H, Diener HC, Joyner CD, Wallentin L, RE-
LY steering committee and investigators: 
Dabigatran versus warfarin in patients with 
atrial fibrillation. N Engl J Med 2009;  361: 
 1139–1151.
 32 Rizos T, Herweh C, Jenetzky E, Lichy C, 
Ringleb PA, Hacke W, Veltkamp R: Point-of-
care international normalized ratio testing 
accelerates thrombolysis in patients with 
acute ischemic stroke using oral anticoagu-
lants. Stroke 2009;  40:  3547–3551.
 
